Last updated on April 18, 2014 at 17:24 EDT

Gregory Lucier Joins RainTree Oncology Board Of Directors

September 23, 2013

SAN DIEGO, Sept. 23, 2013 /PRNewswire/ — RT Oncology Services Corporation today announced that it has elected Gregory T. Lucier to its board of directors. Lucier is the chairman of the board and chief executive officer of Life Technologies Corporation.

RainTree Oncology and Life Technologies recently announced a collaboration designed to advance personalized care for cancer patients. RainTree Oncology is actively building an infrastruction of collaborators from throughout the industry to support its nationwide network of approximately 800 total physicians, the majority of which are medical oncologists, in approaching 50 practices.

“Greg has applied his more than 25 years of strategic management at Life Technologies to shaping an era of personalized medicine, while building a company known for excellence in its products and breakthrough discoveries,” said Mike Martin, RainTree Oncology president and chief executive officer. “His knowledge, relationships and guidance will be of great value as we continue to execute our vision of revolutionizing community oncology practice performance and patient care.”

“RainTree Oncology and Life Technologies share a commitment to making cancer a manageable, treatable disease,” said Lucier. “It is a privilege to contribute to the fine work that RainTree is doing on the front of elevating cancer care in the community setting, where most patients are treated.”

Lucier has been chairman of the board and chief executive officer of Life Technologies since 2003. With a presence in more than 180 countries, the company’s portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum–scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research.

Lucier is chairman of the board at Sanford-Burnham Institute and also serves on the boards of CareFusion Corporation, a New York Stock Exchange Company, Synthetic Genomics Inc., and Rady Children’s Hospital.

About RainTree Oncology Services
RainTree Oncology Services is the nation’s leading community oncology alliance, assisting its member practices in achieving better and more cost-effective treatment of oncology patients while creating new streams of revenue for community oncology practices. RainTree Oncology achieves this by negotiating and administering favorable GPO contracts; by implementing technology allowing RainTree Oncology members to develop and evaluate care pathways to improve patient care and outcomes while reducing costs to the healthcare system; and by developing commercial relationships that accelerate innovative oncology treatments and payer arrangements while optimizing oncology patient care and advancing the science of oncology. For more information about RainTree Oncology Services visit www.raintreeoncology.com.

SOURCE RainTree Oncology Services

Source: PR Newswire